Table 3.

Site-specific 5-year cumulative incidence of recurrence between procedures in patients with pN0 lung adenocarcinoma: Occult lymph node metastasis risk-based recurrence pattern assessment

		MLN evaluation (+)a			MLN evaluation (−)c
Cohort, site	Lobectomy	Segmentectomy	Wedge	Pb	Wedge	Pd
Overall	N=680	N=123	N=91		N=161
Local (treated lobe)	0 (N/A)	3 (1–9)	5 (2–14)	<0.001	14 (9–21)	<0.001
Regional LN (ipsilateral hilar/mediastinal)	1 (1–3)	4 (1–10)	8 (3–19)	0.011	14 (9–21)	<0.001
Regional lung (ipsilateral another lobe)	3 (2–5)	2 (0–7)	1 (0–9)	0.7	7 (3–13)	0.053
Distant	9 (7–12)	7 (4–14)	12 (6–23)	0.5	12 (8–20)	0.3
High ONM risk (STAS positive)	N=263	N=37	N=34		N=75
Local (treated lobe)	0 (N/A)	3 (0–20)	8 (2–32)	<0.001	23 (14–36)	<0.001
Regional LN (ipsilateral hilar/mediastinal)	2 (1–6)	9 (3–26)	21 (9–50)	<0.001	22 (14–35)	<0.001
Regional lung (ipsilateral another lobe)	5 (3–10)	6 (1–22)	3 (0–24)	0.9	11 (5–23)	0.4
Distant	14 (10–19)	11 (4–29)	22 (10–50)	0.7	21 (13–35)	0.5
Low ONM risk (STAS negative)	N=417	N=86	N=57		N=86
Local (treated lobe)	0 (N/A)	3 (1–12)	4 (1–17)	0.002	7 (3–15)	<0.001
Regional LN (ipsilateral hilar/mediastinal)	1 (0–3)	2 (0–12)	0 (N/A)	0.8	6 (3–15)	<0.001
Regional lung (ipsilateral another lobe)	1 (0–3)	0 (N/A)	0 (N/A)	0.5	3 (1–10)	0.3
Distant	6 (4–9)	6 (2–15)	7 (3–19)	0.7	5 (2–13)	0.9

Data are % (95% confidence interval). LN, lymph node; MLN, mediastinal lymph node; N/A, not applicable; ONM, occult lymph node metastasis; STAS, spread through air spaces.

^aPathologic evaluation of at least one MLN by either dissection or sampling.

^bComparison between three procedures with MLN evaluation.

^cNo pathologic evaluation of MLNs.

^dComparison between four procedures, including wedge resection without MLN evaluation.